Methodsurgical

About Methodsurgical

Method AI is a medical technology company developing an AI-powered surgical navigation platform to enhance visualization in robotic-assisted oncology procedures. The company was founded in 2021 as a spin-off from the Cleveland Clinic by CEO Doug Teany, a robotics expert and former COO of Corindus, and Dr. Jihad Kaouk, a urologist. Based near Boston, Method AI aims to solve the challenge of surgeons having an incomplete view of tumors during complex operations, particularly in oncology.

The company's core technology utilizes continuous 3D ultrasound imaging and machine learning algorithms to create a real-time, 3D subsurface map of an organ. This platform provides surgeons with real-time guidance based on an AI-generated surgical plan, visualizing anatomy that is deep below the visible surface and beyond the scope of current surgical cameras. The goal is to help surgeons more accurately gauge tumor margins, reduce the chances of leaving cancerous tissue behind, minimize complications, and preserve organ function. By improving precision in tumor removal, the company aims to significantly improve cancer-free survival rates and potentially lower annual healthcare costs by over $1 billion.

Method AI's business model is B2B, targeting hospitals and healthcare providers that perform robotic surgeries. In August 2025, the company secured $20 million in a Series A funding round led by a private family office, with participation from the Cleveland Clinic and the JobsOhio Growth Capital Fund. This capital is intended to support the continued development of its novel surgical ultrasound platform. The platform is currently under development and has not yet been cleared for commercial distribution.